Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flumetasone pivalate + clioquinol is a fixed-dose ear drop combination of a synthetic difluorinated glucocorticoid (flumetasone pivalate) and a halogenated hydroxyquinoline derivative (clioquinol). Flumetasone pivalate acts as a potent topical anti-inflammatory, anti-allergic, and vasoconstrictive corticosteroid, providing rapid relief of inflammatory symptoms such as pruritus, redness, and swelling. Clioquinol exhibits broad-spectrum antibacterial and antifungal (antimycotic) activity, especially against common otitis externa pathogens including Gram-positive bacteria (notably Staphylococci), certain Gram-negative bacteria, and dermatophyte and yeast fungi (such as Candida, Microsporum, Trichophyton). This combination is indicated for the treatment of otitis externa, otomycosis, and eczema of the external auditory canal with suspected or confirmed secondary infection[1][4][5][7][9]. The medication is applied directly into the external ear canal and is not recommended for children under 2 years.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on flumetasone pivalate + clioquinol.